NUVB peer analysis
Nuvation Bio (NUVB) against its competitors: price, today's move, 1-year return and market value side by side.
NUVB and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABCL AbCellera | $11.86 | 6.57% | 150.53% | – |
| AUPH Aurinia Pharmaceuticals | $16.46 | 1.54% | 14.05% | $2.17B |
| CLDX Celldex Therapeutics | $30.00 | 6.12% | 24.10% | $2.22B |
| EWTX Edgewise Therapeutics | $45.28 | 16.48% | 154.52% | – |
| GPCR Structure Therapeutics | $20.00 | 4.82% | -37.53% | – |
| JANX Janux | $17.63 | 9.78% | -39.58% | – |
| OCUL Ocular Therapeutix | $6.65 | 3.45% | -38.67% | $1.41B |
| QURE uniQure | $22.00 | 4.71% | -17.19% | $1.47B |
| VERA Vera Therapeutics | $30.37 | 0.76% | 25.73% | – |
| VRDN Viridian Therapeutics | $28.48 | -0.25% | 19.00% | – |
| NUVB Nuvation Bio | $4.19 | 0.00% | -14.02% | – |
- NUVB's peers: ABCL (AbCellera), AUPH (Aurinia Pharmaceuticals), CLDX (Celldex Therapeutics), EWTX (Edgewise Therapeutics), GPCR (Structure Therapeutics), JANX (Janux), OCUL (Ocular Therapeutix), QURE (uniQure).
Updated 2026-11-07 11:56 UTC